Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized study of bortezomib + dexamethasone + thalidomide versus bortezomib + dexamethasone + thalidomide + cyclophosphamide in newly diagnosed transplant-eligible multiple myeloma
2006-006050-10Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bortezomib, dexamethasone, thalidomide and cyclophosphamide in multiple myeloma (MM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Overall combined complete response rate after induction and Overall combined complete response rate after HDT/SCT. Started Jul 2007; status: completed.
02
Drugs
bortezomibdexamethasonethalidomidecyclophosphamide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2006-006050-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006050-10.